MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas

被引:57
作者
Gill, JH [1 ]
Kirwan, IG
Seargent, JM
Martin, SW
Tijani, S
Anikin, VA
Mearns, AJ
Bibby, MC
Anthoney, A
Loadman, PM
机构
[1] Univ Bradford, Canc Res UK Labs, Tom Connors Canc Res Ctr, Bradford BD7 1DP, W Yorkshire, England
[2] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England
[3] Bradford Royal Infirm, Dept Histopathol, Bradford BD9 6RJ, W Yorkshire, England
[4] Bradford Royal Infirm, Dept Cardiothorac Surg, Bradford BD9 6RJ, W Yorkshire, England
来源
NEOPLASIA | 2004年 / 6卷 / 06期
关键词
matrix metalloproteinase; MMP-10; non small cell lung carcinoma; tumor development; molecular target;
D O I
10.1593/neo.04283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix is a major factor for tumor development and expansion. This study analysed MMP-10 protein expression and activity in human lung tumors of various grade, stage, and type to address the relationship between MMP-10 and tumor characteristics and to evaluate MMP-10 as a therapeutic target in non small cell lung carcinoma (NSCLC). Unlike the majority of MMPs, MMP-10 was located in the tumor mass as opposed to tumor stroma. MMP-10 protein was observed at low levels in normal human lung tissues and at significantly higher levels in all types of NSCLC. No correlation was observed between MMP-10 protein expression and tumor type, stage, or lymph node invasion. To discriminate between active and inactive forms of MMP-10 in samples of human NSCLC, we have developed an ex vivo fluorescent assay. Measurable MMP-10 activity was detected in 42 of 50 specimens of lung cancer and only 2 of 10 specimens of histologically normal lung tissue. No relationship was observed between MMP-10 activity levels and clinicopathologic characteristics. Our results suggest that MMP-10 is expressed and active at high levels in human NSCLC compared to normal lung tissues, and, as such, is a potential target for the development of novel therapeutics for lung cancer treatment.
引用
收藏
页码:777 / 785
页数:9
相关论文
共 34 条
[1]  
Bodey B, 2001, IN VIVO, V15, P175
[2]   Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: Potential roles in skeletal development [J].
Bord, S ;
Horner, A ;
Hembry, RM ;
Compston, JE .
BONE, 1998, 23 (01) :7-12
[3]   MMP expression profiling in recurred stage IB lung cancer [J].
Cho, NH ;
Hong, KP ;
Hong, SH ;
Kang, S ;
Chung, KY ;
Cho, SH .
ONCOGENE, 2004, 23 (03) :845-851
[4]  
Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086
[5]   Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer [J].
Duffy, MJ ;
Duggan, C ;
Maguire, T ;
Mulcahy, K ;
Elvin, P ;
McDermott, E ;
Fennelly, JJ ;
OHiggins, N .
ENZYME & PROTEIN, 1996, 49 (1-3) :85-93
[6]   Metalloproteinases: role in breast carcinogenesis, invasion and metastasis [J].
Duffy, MJ ;
Maguire, TM ;
Hill, A ;
McDermott, E ;
O'Higgins, N .
BREAST CANCER RESEARCH, 2000, 2 (04) :252-257
[7]  
Duffy MJ, 1998, CLIN CHEM, V44, P1177
[8]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[9]   Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis [J].
Foda, HD ;
Zucker, S .
DRUG DISCOVERY TODAY, 2001, 6 (09) :478-482
[10]  
Giannelli G, 2001, CLIN EXP METASTAS, V18, P439